Pipeline Discovery Pre-clinical Studies Phase Ⅰ Studies Phase Ⅱ Studies Phase Ⅲ Studies NDA / BLA Market
Ibalizumab (TMB-355) Intravenous Infusion
Ibalizumab (TMB-355) Intravenous Push
Ibalizumab (TMB-355) Intramuscular Injection
TMB-365
TMB-370 (bispecific)
TMB-380 (VRC07-523LS)